The potential impact of new National Osteoporosis Foundation guidance on treatment patterns
- First Online:
- 492 Downloads
This analysis of National Health and Nutrition Examination Survey III data describes the prevalence of risk factors for osteoporosis and the proportions of men and postmenopausal women age 50 years and older who are candidates for treatment to lower fracture risk, according to the new FRAX®-based National Osteoporosis Foundation Clinician's Guide.
Little information is available on prevalence of osteoporosis risk factors or proportions of US men and women who are potential candidates for treatment.
The prevalence of risk factors used in the new National Osteoporosis Foundation (NOF) FRAX®-based Guide to the Prevention and Treatment of Osteoporosis was estimated using data from the third National Health and Nutrition Examination Survey (NHANES III). Risk factors not measured in NHANES III were simulated using World Health Organization cohorts. The proportion of US men and postmenopausal women age 50+ years who are treatment candidates by the new NOF Guide were calculated; for non-Hispanic white (NHW) women, the proportion eligible by the new NOF Guide was compared with that based on an earlier NOF Guide.
Twenty percent of men and 37% of women were potential candidates for treatment to prevent fractures by the new NOF Guide. Among NHW women, 53% were potential candidates by the previous NOF Guide compared with 41% by the new guide.
One fifth of men and 37% of postmenopausal women are eligible for osteoporosis treatment consideration by the new NOF Guide. However, fewer NHW women are eligible by the new guide than by the previous NOF Guide.
KeywordsNational Osteoporosis Foundation Clinician's Guide Osteoporosis Osteoporosis risk factors Prevalence Treatment eligibility ± population-based study
- 4.National Osteoporosis Foundation (2008) Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, D C, pp 1–36Google Scholar
- 5.Kanis J (2008) Assessment of osteoporosis at the primary health-care level. WHO Collaborating Centre, University of Sheffield, Sheffield, UK In Group WHOSGoogle Scholar
- 7.National Osteoporosis Foundation (2005) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DCGoogle Scholar
- 9.Gunter EW, Lewis BG, Koncikowski SM (1996) Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. In Services DoHaH (ed). Center for Disease Control and Prevention, Atlanta, GAGoogle Scholar
- 10.(1977) Standards and guidelines for federal statistics: race and ethnic standards for federal statistics and administrative reporting. In Budget OoMa (ed). Federal Register.Google Scholar
- 14.Denniston PL, Epner JA (1993) 1993 physicians' GenRx. Data Pharmaceutica, New YorkGoogle Scholar
- 17.Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15–25CrossRefPubMedGoogle Scholar
- 18.Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, Burckhardt P, Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ 3rd, Pols H, Reeve J, Sanders K, Schott AM, Silman A, Torgerson D, van Staa T, Watts NB, Yoshimura N (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046CrossRefPubMedGoogle Scholar
- 19.Ettinger D, Black D, Dawson-Hughes B, Pressman AR, Melton LJ (2009) Updated fracture incidence rates for the U.S. version of FRAXR. Osteoporos Int doi:10.1007/s00198-009-1032-9
- 24.Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Black DM, Bauer DC, Cummings SR (2009) Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. national osteoporosis foundation guidelines. J Bone Miner Res 24:675–680CrossRefPubMedGoogle Scholar